Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

Colliers buys half interest in Cleveland firm

Article Abstract:

Colliers Macaulay Nicolls, a Vancouver, British Columbia-based company that does business as Colliers International, has purchased a 50% stake in Ostendorf-Morris, a Cleveland, OH-based commercial property services firm. Colliers Macaulay, which is the biggest member of Colliers International Property Consultants of San Francisco, CA, declined to disclose financial terms of the acquisition but noted Ostendorf-Morris generated revenue of $12 million in 1997. Ostendorf-Morris Chairman and CEO Bill West stated the sale to Colliers Macaulay allows his company to expand the services it can offer to clients worldwide, particularly in North America.

Comment:

Buys 50% stake in OstendorfMorris, a Cleveland, OH-based commercial property services firm

Author: Zehr, Leonard
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
Asset sales & divestitures, Acquisitions & mergers, Real Estate Agents, Brokers, Managers, Real Estate, Real estate agents, Real estate management, Ostendorf-Morris Co., Colliers Macaulay Nicolls International

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


New treatment can fight E. Coli: Nymox

Article Abstract:

Nymox Pharmaceutical Corp. of Rockville, MD, has come up with a new treatment that can fight the E. Coli bacteria. The new anti-bacterial, called NXC4720, fights E. Coli 0157, including the H7 strain, which is found on hamburger patties. According to the company's medical director, Michael Munzar, the treatment is non-toxic and a very useful host range. Studies showed that NXC4720 could be a potential fighter against the bacteria in animals, meat processing plants and other contaminated sources.

Comment:

Has come up with a new treatment that can fight the E. Coli bacteria

Author: Zehr, Leonard
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
Pharmaceutical Preparation Manufacturing, Antibacterial & Antiseptic Preps, Anti-infective agents, Nymox Pharmaceutical Corp.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Que. tech firm hits new high

Article Abstract:

The U.S. has given TSO3 Inc. permission to market its medical sterilization device to hospitals that use ozone gas. The device sterilizes diagnostic and surgical equipment. The news caused TSO3's share value to reach a 52-week high on September 3, 2003.

Author: Zehr, Leonard
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2003
Securities issued, listed, Product information, Securities, Medical equipment and supplies industry, Medical equipment industry, Company securities, Medical equipment sterilization, TSO3 Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Canada, Article
Similar abstracts:
  • Abstracts: RIM stock price slides on court's patent ruling. Latest loss in patent war renews RIM's fight with NTP
  • Abstracts: Bain beats Yellow Pages in SuperPages battle. New contract a fait accompli, Telus says. Telecom rivals BCE, Telus jockey for Olympic gold
  • Abstracts: Hot cars put Chrysler Ontario plant in overdrive. End of an era - bit three are no more. Big Three market share declines
  • Abstracts: Bombardier seeks damages over jet part. Air Canada forced to cancel flights
  • Abstracts: Judge Says Maker Of OxyContin Misled Officials To Win Patents. No Damages In Rosie Case, Judge Hints
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.